5-hydroxytryptamine subtype 6 receptor modulators: a patent survey.
BACKGROUND
Among the GPCR subclasses that have been discovered to date, 5-HT receptors are especially attractive as key biological targets with enormous clinical importance. In particular, during the last decade, the 5-HT(6) receptor has gained increasing attention due to extensive cellular functions. It has also been suggested that its activity can be mediated by inverse agonists.


METHODS
Summarizing the points listed above, the current review primarily focuses on patent literature within the title field, evolution and trends that have not yet been covered in such depth in other published papers.


RESULTS
To obtain a clear understanding of the situation and dynamics within the field of 5-HT(6) ligands, having an obvious pharmaceutical potential in terms of related patents, we provide a comprehensive search through several key patent collections. We have covered promising small molecule compounds which are being evaluated in different clinical trials as well as drugs currently available in the pharmaceutical market. In addition, readers will gain a deep insight into the patent specification, geographic distribution, tendency and patent holders presented.


CONCLUSIONS
Several of 5-HT(6)-targeted compounds are reasonably regarded as powerful drug candidates for the treatment of a range of neuropathological disorders, including Alzheimer's disease and Huntington's disease.
Ivachtchenko
Alexandre V
AV
ChemDiv, Inc., 6605 Nancy Ridge Drive, San Diego, CA 92121, USA. av@chemdiv.com
Ivanenkov
Yan A
YA
Tkachenko
Sergey E
SE
D000818:Animals; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D015195:Drug Design; D054314:Drug Inverse Agonism; D006801:Humans; D008024:Ligands; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000503:physiopathology; D010330:Patents as Topic; D011985:Receptors, Serotonin / Q000187:drug effects* / Q000378:metabolism
D008024:Ligands; D011985:Receptors, Serotonin; C097216:serotonin 6 receptor